Tirzepatide Injection 7.5mg

Key Selling Points of Tirzepatide for Diabetes and Obesity Management

1. Innovative Dual Receptor Mechanism

• First-in-Class Dual Agonist: Tirzepatide is the world’s first dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.

  ◦ GLP-1 Receptor: Delays gastric emptying, inhibits glucagon secretion, and stimulates insulin release to lower blood sugar.

  ◦ GIP Receptor: Enhances insulin sensitivity, promotes fat metabolism, and increases energy expenditure, synergizing with GLP-1 for superior metabolic control.

• Precision Metabolic Regulation: Mimics natural GIP/GLP-1 pathways to simultaneously improve glycemic control, reduce weight, and optimize lipid/energy balance.

2. Clinically Proven Efficacy

• Exceptional Blood Sugar Control:

  ◦ Reduces HbA1c by 1.5%–2.0% in type 2 diabetes patients, outperforming many single-receptor therapies.

  ◦ Helps patients achieve glycemic targets faster, even when prior treatments fail.

• Powerful Weight Loss:

  ◦ Leads to 15% or more weight reduction in obese/overweight patients in long-term studies, with sustained effects.

  ◦ Suppresses appetite and increases satiety, addressing the root cause of overeating.

• Cardiovascular & Metabolic Benefits:

  ◦ Lowers triglycerides, LDL cholesterol, and blood pressure, reducing cardiovascular risk.

3. Convenient and Patient-Friendly Administration

Function and Indications

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus by mimicking the action of natural GIP and GLP-1, promoting insulin secretion, inhibiting glucagon release, and delaying gastric emptying.

Applicable Population

• Primary Use: Adults with type 2 diabetes who have inadequate glycemic control through lifestyle modifications alone.

• Additional Use: Adults with obesity (BMI ≥28 kg/m²) or overweight (BMI ≥24 kg/m²) and at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, obstructive sleep apnea), for weight management.

Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

• Hypersensitivity to tirzepatide or any excipients.

Usage and Dosage

• Starting Dose: 2.5 mg once weekly, administered subcutaneously.

• Dose Titration: After 4 weeks, increase to 5 mg/week; may further increase by 2.5 mg/week (to a maximum of 15 mg/week) based on glycemic control or weight loss response.

• Administration: Inject into the abdomen, thigh, or upper arm; rotate injection sites to avoid skin reactions.

Adverse Reactions

• Common (≥5%): Nausea, vomiting, diarrhea, abdominal pain, constipation, headache, fatigue.

• Serious Risks:

  ◦ Thyroid C-cell tumors: Observed in animal studies; contraindicated in patients with MTC history/family history.

  ◦ Hypoglycemia: Increased risk when combined with insulin secretagogues (e.g., sulfonylureas) or insulin.